fall 2015 exam 2 omsii clis. clostridia spp. ○ pathogens: ○ gram +, anaerobic, spore-forming...
DESCRIPTION
Chlamydia spp. ○ Pathogen: ○ Obligate intracellular gram-negative bacteria ○ Encounter: ○ Genital, ocular, respiratory infections in humans ○ Certain animal and avian isolates cause disease ○ Entry: ○ Sexually transmitted ○ Human-to-human droplet spread ○ Contact with infected animals ○ Spread: ○ Undergo unique developmental cycle within eukaryotic host cells ○ Multiplication: ○ 2 distinct morphological forms: ○ Elementary bodies (EB) –enfectious small extracellular infectious particles that attach to and enter into host cells but are metabolically inert (do not grow or divide) ○ Reticulate bodies (RB) – replicate. derived from EBs after uptake by cells; larger, intracellular, noninfectious but metabolically active forms; divide by binary fission within membrane-bound inclusion in eukaryotic host cells ○ Damage: ○ Most damage related to host hypersensitivity reaction ○ Diagnosis: ○ PCR (genital infection) or serologic diagnosis ○ Treatment and prevention: ○ Chlamydiae are sensitive to macrolides, tetracyclines, and fluoroquinolonesTRANSCRIPT
Fall 2015 exam 2 OMSII CLIs
Clostridia spp.○ Pathogens:
○ Gram +, anaerobic, spore-forming rods○ C. difficile (antibiotic assocaited diarrhea and pseudomembranous colitis)○ C. perfringens (gas gangrene)○ C. botulinum (botulism, “floppy baby” after honey))○ C. tetani (tetanus)
○ Encounter:○ Mostly acquired from the environment○ colonize mammalian colon and are returned to the environment as spores from the feces
○ Entry:○ Ingestion of clostridial spores in context of antibiotic therapy ○ Contamination of wounds with soil○ Botulism can occur after ingestion of preformed clostridial neurotoxin in contaminated food (does
not necessarily change appear or taste of food)○ Spread and multiplication:
○ Grow in anaerobic environment of GI or devitalized, anaerobic tissue of necrotic wound○ Damage:
○ Expression of disease depends on production of clostridial cytotoxins of neurotoxins○ Diagnosis:
○ For wounds: gram stains and culture under anaerobic conditions○ C. diff infection usually diagnosed by detecting toxins in feces○ Neurotoxic clostridial infections (tetanus- SPASMOTIC PARALYIS via GABA Inhibition and botulism-
FLACCID PARALYSIS via inhibiting ACH release)○ Treatment :
○ Wound infections – surgical debridement of tissues○ C. diff infection – metronidazole or vancomycin (PO only!)○ Tetanus and botulism – antitoxins
○ Prevention:○ Sterility in canning foods to prevent contamination with C. botulinum spores○ “toxoid” vaccine prevents tetanus○ Proper wound management○ Judicious use of antibiotics
Chlamydia spp.○ Pathogen:
○ Obligate intracellular gram-negative bacteria○ Encounter:
○ Genital, ocular, respiratory infections in humans○ Certain animal and avian isolates cause disease
○ Entry:○ Sexually transmitted○ Human-to-human droplet spread○ Contact with infected animals
○ Spread:○ Undergo unique developmental cycle within eukaryotic host cells
○ Multiplication:○ 2 distinct morphological forms:
○ Elementary bodies (EB) –enfectious small extracellular infectious particles that attach to and enter into host cells but are metabolically inert (do not grow or divide)
○ Reticulate bodies (RB) – replicate. derived from EBs after uptake by cells; larger, intracellular, noninfectious but metabolically active forms; divide by binary fission within membrane-bound inclusion in eukaryotic host cells
○ Damage:○ Most damage related to host hypersensitivity reaction
○ Diagnosis:○ PCR (genital infection) or serologic diagnosis
○ Treatment and prevention:○ Chlamydiae are sensitive to macrolides, tetracyclines, and fluoroquinolones
Candida spp.○ Pathogen:
○ Round or oval yeasts that reproduce by forming buds or blastoconidia○ Potential to form hyphae in vivo○ C. albicans (most infections), C. glabrata (resistant to some antifungal agents), C.
parapsilosis (central venous catheter associated infections)○ Encounter:
○ Normally colonize GI tract (mouth to rectum), vagina, and skin○ Most infections endogenous○ Immunosuppressed (especially neutropenic and ICU patients.)○ Risk factors: broad-spectrum antibiotics, renal failure requiring dialysis, central venous catheters,
parenteral nutrition○ Entry:
○ Disruption of normal flora will cause opportunistic infection○ Decreased T- cell immunity allows proliferation○ Neutropenia and central venous catheters
○ Spread and multiplication:○ Main host defense in T-cell mediated immunity (protects against mucosal surfaces)○ Neutrophils protect from spread through mucosa and subsequent dissemination
○ Damage:○ Mucosal candidiasis – adherent white plaques on oropharyngeal and vaginal mucosa (thrush); non-
painful○ Proliferation in warm moist areas (intertriginous candidiasis and diaper rash)○ Underlying tissues are not damaged○ Candidemia is dissemination which can cause microabscesses in many organs, meningitis,
chorioretinitis and vitritis, hepatosplenic abscesses, and vertebral osteomyelitis. Endocarditis on prosthetic valves.
○ Diagnosis:○ Scrapings of lesion show budding yeast and pseudohyphae○ Blood culture for disseminated candidiasis with blood agar or Sabouraud agar (selective for
fungi).○ C. albicans can be differentiated by development of germ tubes when exposed to calf
serum○ Treatment and prevention:
○ Local antifungal topical creams/powders○ Invasive/disseminated infection can be treated with systemic fungal agent fluconazole or
amphotericin B
Aspergillus spp.○ Pathogen:
○ Filamentous fungi that form mycelium of septate hyphae○ Reproduce by forming conidia on aerial conidiophores○ Major pathogenic species are A. fumigatus and A. flavus○ Not part of normal flora of humans
○ Encounter:○ Ubiquitous in soil, manure, and decomposing vegetation○ Usual hosts are those who are neutropenic, on corticosteroids, or other immunosuppressive
drugs, or transplant recipients○ Entry:
○ Conidia are inhaled into upper and lower respiratory tracts○ After entry is germination of conidia into hyphae which then invade tissues
○ Spread and multiplication:○ Neutrophils and macrophages are main host defense○ Angioinvasive fungus which can cause tissue infarction, hemorrhage, and necrosis
○ Damage:○ Presents initially as pulmonary or sinus infection○ Histopathologically seen are hemorrhagic infarction and necrosis; acutely branching septate
hyphae seen invading through tissues○ Invasive pulmonary aspergillosis will show fever, pleuritic chest pain, cough, hemoptysis, and
dyspnea○ Disseminated aspergillosis include: necrotic skin lesions and brain abscess
○ Diagnosis:○ Grow on Sabouraud agar○ Tissue biopsy for tissue invasion
○ Treatment:○ Invasive aspergillosis – voriconazole, amphotericin B, or echinocandin is used○ Empiric treatment often initiated based on clinical manifestations and CT scan results
Plasmodium○ Organism:
○ Protozoa○ Malaria caused by P. falciparum, P. vivax, P. ovale, and P. malariae
○ Encounter and entry:○ Transmission through bite of infected female anopheline mosquitoes
(saliva)○ Spread and multiplication:
○ Sporozoite is the infectious form present in mosquitoes that is transmitted to humans
○ Sporozoites enter liver cells which mature, multiply, and are released as merozoites (form that invades RBCs)
○ Merozoites divide and mature inside RBCs and release new infective merozoites; a minority form gametocytes
○ Damage:○ Fever, chills, anemia○ Can cause splenomegaly
○ Diagnosis:○ Giemsa-stain○ P. vivax have Schüffner dots
○ Treatment:○ Chloroquine○ Chloroquine resistant P. falciparum can be treated with Malarone, Coartem,
quinine + doxycycline, or quinidine
TrypanosomesT. cruzi (Chagas disease)
○ Pathogenesis:○ Bite of infected reduviid bug (“kissing bug”) (fecal matter)○ Chancre or tissue and lymph node swelling at bite site○ Most develop mild disease w/ fever, recover spontaneously, and remain
asymptomatic○ Small proportion develop complications 10-20 years later
○ damage to nerves in GI tract (megaesophagus, megacolon)○ Conducting tissue in heart (right bundle branch block)○ Heart muscle (cardiomyopathy)
○ Fibrosis is the hallmark of pathology○ Diagnosis and treatment:
○ Blood culture, positive antibody titer○ Treat with nifurtimox or benznidazole○ No treatments for late complications
T. Brucei (African sleeping sickness)○ Pathogenesis and diagnosis:
○ Bite of infected tsetse flies (saliva)○ Undergo antigenic variation of its immunodominant surface antigen
(variable surface glycoprotein)○ Reservoirs are wild game animals in East Africa (takes only months
to reach CNS); humans and domestic animals in West Africa (takes years to reach CNS)
○ Bouts of systemic illness with fever and swollen lymph nodes; can eventually reach brain and CNS and infect brain and spinal fluid. During each bout, undergo surface antigen rearrangement (genetic rearrangement).
○ Treatment:○ eflornithine
Adenovirus○ Pathogens:
○ Large, nonenveloped, DNA viruses with icosahedral symmetry○ Encounter:
○ Respiratory serotypes: exposure to aerosols or infected fluids (saliva)○ Enteric types: contamination with fecal matter
○ Entry:○ Initial site of replication in most cases is probably oropharynx
○ Spread:○ Most often cause mild infection of respiratory and GI systems○ Severe infections can cause keratoconjunctivitis and acute, severe
pneumonia○ Replication:
○ Temporal regulation of gene expression dependent upon viral regulatory genes
○ Employ both virally encoded and host proteins in the replication process○ Damage:
○ Evade antiviral host defenses (prevent host cells from expressing MHC proteins, mediate resistance to TNF, abrogate interferon response, and antigenic diversity)
○ Infection can be fatal in immunocompormised○ Diagnosis:
○ Recognition of clinical features○ Lab Dx not typically done except life-threatening situations (PCR)
○ Treatment/Prevention:○ No vaccine available○ No antiviral drug
Influenza virus○ Pathogen:
○ Segmented negative-sense RNAs○ 3 types: A, B, and C (type A can infect animals)○ Possess hemagglutinin (HA) and neuraminidase (NA) as
major surface antigens○ antigenic drift is caused by yearly accumulation of mutations in
HA and NA○ Antigenic shift results from acquisition of a novel HA and NA by
the virus○ Encounter: influenza occurs in epidemics and pandemics in
the winter (seasonality) [Oct-April Peak incidence in December. ]
○ Entry: person-to-person and respiratory droplets that infect URT and LRT
○ Spread: cell infection initiated by attachment of the viral HA to sialic acid-containing glycoproteins or glycolipids and subsequent uptake into an endocytic vesicle
○ Replication: gene transcription and RNA replication occur in the nucleus
○ Damage: causes clinical symptoms, including common cold, pharyngitis, tracheobronchitis, and bronchiolitis or croup in children
○ Diagnosis: virus isolation from sputum and nose/throat swabs; rapid diagnostic tests available
○ Treatment/Prevention: ○ rimantadine and amantadine (inhibit viral uncoating after
uptake) -○ These are NA inhibitors (inhibit viral release from infected cell and cause
aggregation of viral particles). So it won’t help symptomatic patients. ○ Vaccines: inactivated vaccine or the live, attenuated, cold-adapted
vaccine
Human Papilloma Virus○ Non enveloped, Double stranded, Circular
○ Soo many serotypes○ Encounter/Entry: direct skin to skin contact ie
sex; enters break in skin and sets in the basal layer of skin
○ Since it is non enveloped, it may live on inanimate objects. ○ Respiratory papillomatous: Vertical transmission during
birth;rare○ Oncogenic properties
○ E6- combines with p53- Induces Ubiquitylation proteolysis pathway and inhibits tumor suppression
○ E7- combines with Rb – prevents Rb exerting its normal check on cell proliferation
○ Damage: Warts or Cancer○ Warts-(serotypes 6, 11)
○ Condyloma Accuminata ○ Cancer
○ CIN, cervical cancer (most commonly 16, 18) ○ Diagnosis:
○ Warts- causing Verrucous finger like projections○ Cancer- shows atypia (Koilocytes),
○ Treatment/Prevention:○ Surgical excision ○ Cryotherapy○ Immunomodulators- Imiquimod○ Or it disappears on its on… via cell mediated response ○ Quad Valent Vaccine – 6/11/16/18 serotype protection. Uses
“ capsid like” proteins
Haemophilus influenzae
• Gram-negative, small rod, nutritionally fastidious [Grows on chocolate agar or on blood with another bacteria that can breakdown blood and provide nutrients]
• Multiple types, only type B has a capsule. It is esp associated with meningitis and there is a vaccine for just that type]
• Encounter: Throat, inhalation, hand contact• Pathogenic mechanism: Inflammation facilitated by resistance to
phagocytosis (capsule), endotoxin, IgA1 protease, pili, outer membrane protein
• Typical Dz: Meningitis (infants, 3mo-2y) w/ sequelae, respiratory infx/COPD exacerbation, cellulitis, epiglottitis [thumbprint sign]
From FA:• Culture on chocolate agar (requires factor V(NAD+) and X (hematin) for
growth)• Vaccine: conjugated polysaccharide vaccine [against type B], given
between 2-18 months
Klebsiella Pneumoniae ○ *** very little mention in the book***○ Pathogen:○ Gram Negative Rod, enteric○ Spread: Typically seen in Community Acquired Pneumonia,
Hospital Acquired Pneumonia ;○ Common Case scenario: chronic alcoholic or Diabetic who
aspirates and makes current jelly sputum○ Damage: Polysaccharide capsules- causing mucoid colonies○ Diagnosis: Xray: Shows FOCAL lobar consolidation
○ 4 A’s of KlebsiellA:○ Aspiration pneumonia○ Abscess in lungs and liver○ Alcoholics○ di-A-betics